Worth reading
45Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Agreements reached under this partnership
Business alliance4586Medrx Co.,Ltd.
Alliance partnerTerrain Pharmaceuticals
Details of the alliance
- 1
U.S. sales partnership for Bondlido
- 2
Discussions toward entering into a sales license agreement
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
About the partner
Business DescriptionA U.S. specialty pharmaceutical company with more than 10 years of experience developing and marketing topical analgesics. Through a nationwide distribution network that includes independent retail pharmacies, specialty pharmacies and healthcare institutions, it markets prescription and over-the-counter topical patches and semisolid formulations, including lidocaine- and NSAID-based products.
LocationReno, Nevada, U.S.
Impact on Business Performance
The impact on our results for the fiscal year ending December 2026 is expected to be immaterial.
Contract DateAs of the disclosure dated 15 May 2026, a legally binding term sheet had been signed. The sales license agreement is expected to be signed in October 2026.
| Item | Details |
|---|---|
| Name of alliance partner | Terrain Pharmaceuticals |
| Alliance partner's business activities | A U.S. specialty pharmaceutical company with more than 10 years of experience developing and marketing topical analgesics. Through a nationwide distribution network that includes independent retail pharmacies, specialty pharmacies and healthcare institutions, it markets prescription and over-the-counter topical patches and semisolid formulations, including lidocaine- and NSAID-based products. |
| Alliance partner's location | Reno, Nevada, U.S. |
| Type of alliance | Business alliance |
| Details of the alliance | U.S. sales partnership for Bondlido, Discussions toward entering into a sales license agreement |
| Contract Date | As of the disclosure dated 15 May 2026, a legally binding term sheet had been signed. The sales license agreement is expected to be signed in October 2026. |
| Impact on Business Performance | The impact on our results for the fiscal year ending December 2026 is expected to be immaterial. |
Items this document does not state (16)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales volumes over the next several years are expected to exceed the assumptions made when the term sheet was signed, and the sales strategy, supply plan and contractual terms are being reviewed. In addition, adjusting the contractual terms is taking longer than expected.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.